This is the authors' abstract. We don't add key points for this paper.
Objective: This study aims to evaluate whether extended lymph node dissection (ePLND) improves overall survival (OS) and oncological outcomes compared with standard dissection (sPLND) in patients undergoing radical cystectomy for urothelial bladder cancer. Methods: A systematic review and meta-analysis were conducted according to PRISMA 2020 (PROSPERO CRD420261309465). PubMed/MEDLINE, EMBASE, Cochrane Library and Web of Science were searched. RCTs and observational studies comparing ePLND and sPLND were included. The primary outcome was OS; secondary outcomes included recurrence-free survival (RFS), cancer-specific survival (CSS), 5-year OS, 5-year RFS, major complications and lymphocele. A random-effects model was used, with sensitivity analyses and meta-regression. Risk of bias was assessed using RoB 2 and ROBINS-I. No consistent benefit was observed for 5-year OS, although recurrence was reduced. ePLND did not significantly affect major complications. Sensitivity analyses confirmed result stability. Conclusion: Higher quality evidence does not demonstrate a consistent benefit of ePLND for OS, although overall analyses show reduced recurrence. Current data do not support the routine adoption of ePLND with the sole objective of improving survival.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gordilho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: